

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

HALL A

BIG CONTROVERSIES IN RETINA IN 2021

Friday August 20, 2021		Hall A
11:00-12:30	Big Controversies in Retina in 2021	
Chairs:	<u>Neil Bressler, USA</u>; <u>Anat Loewenstein, Israel</u>	
11:00-11:05	Open Remarks: <u>Neil Bressler, USA</u> & <u>Anat Loewenstein, Israel</u>	
11:05-11:30	Debate 1: Moderate to Severe Non-proliferative Diabetic Retinopathy Without Macular Edema Should Be Treated Prophylactically with Anti-VEGF Agents	
11:05-11:15	Yes: <u>Diana Do, USA</u>	
11:15-11:25	No: <u>Sobha Sivaprasad, UK</u>	
11:25-11:30	Discussion (5 mins)	
11:30-12:00	Debate 2: When Approved, Slow Release Devices Should Replace Most Intravitreal Injections for Neovascular AMD	
11:30-11:40	Yes: <u>Anat Loewenstein, Israel</u>	
11:40-11:50	No: <u>Peter Kertes, Canada</u>	
11:50-12:00	Discussion	
12:00-12:30	Debate 3: Treating Proliferative Diabetic Retinopathy: Combining Anti-VEGF with PRP is Preferred Over Monotherapy (Anti-VEGF or PRP)	
12:00-12:10	Yes: <u>Baruch Kupperman, USA</u>	
12:10-12:20	No: <u>Paolo Lanzetta, Italy</u>	
12:20-12:30	Discussion	
12:30-13:00	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

MEDICAL RETINA 1 | Neovascular (“Wet”) AMD Management

Friday August 20, 2021		Hall A
13:00-14:30	MEDICAL RETINA 1 Neovascular (“Wet”) AMD Management	
Chairs:	<u>Susan Bressler, USA</u> ; <u>Stela Vujosevic, Italy</u> ; <u>Tien Yin Wong, Singapore</u>	
13:00-13:30	Debate 1: Intraocular Inflammation is a New Problem to Consider when Evaluating New Agents for Neovascular AMD	
13:00-13:10	Yes: <u>Stela Vujosevic, Italy</u>	
13:10-13:20	No: <u>Giuseppe Querques, Italy</u>	
13:20-13:30	Discussion	
13:30-14:00	Debate 2: “Treat and Extend” is a superior approach to “PRN”	
13:30-13:40	Yes: <u>Tien Yin Wong, Singapore</u>	
13:40-13:50	No: <u>Susan Bressler, USA</u>	
13:50-14:00	Discussion	
14:00-14:30	Debate 3: Treatment of Non-exudative CNV should Begin when Detected on OCT, Even in the Absence of Symptoms or Fluorescein Leakage	
14:00-14:10	Yes: <u>Voraporn Chaikitmongkol, Thailand</u>	
14:10-14:20	No: <u>Usha Chakravarthy, UK</u>	
14:20-14:30	Discussion	
14:30-15:00	<i>Visit Companies Information Corner and ePosters</i>	
15:00-16:00	Industry-Sponsored Symposium	
16:00-16:15	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

VISION ACADEMY

Friday August 20, 2021		Hall A
16:15-17:15	Controversies Inspired by the Vision Academy	
Chairs:	<u>Neil Bressler, USA; Anat Loewenstein, Israel</u>	
16:15-16:20	An introduction to the Vision Academy: <u>Neil Bressler, USA</u>	
16:20-16:45	Debate 1: Should Anti-VEGF Therapy Be Tailored To Neovascular AMD Subtypes?	
16:20-16:25	Yes: <u>Jean-François Korobelnik, France</u>	
16:25-16:30	No: <u>Kenneth Fong, Malaysia</u>	
16:30-16:35	Presentation of Viewpoint: <u>Anat Loewenstein, Israel</u>	
16:35-16:45	Questions	
16:45-17:10	Debate 2: Management of Subfoveal Hemorrhage from Neovascular AMD: Start with Surgery, or with Anti-VEGF?	
16:45-16:50	Yes: <u>Paisan Ruamviboonsuk, Thailand</u>	
16:50-16:55	No: <u>Richard Gale, UK</u>	
16:55-17:00	Presentation of Viewpoint: <u>Anat Loewenstein, Israel</u>	
17:00-17:10	Questions	
17:10-17:15	Looking Forward with the Vision Academy: <u>Anat Loewenstein, Israel</u>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

MEDICAL RETINA 2 | Diabetic Macular Edema (DME)

Saturday August 21, 2021		Hall A
11:00-12:30	MEDICAL RETINA 2 Diabetic Macular Edema and Proliferative Diabetic Retinopathy	
Chairs:	<u>Luis Arias, Spain; Paolo Lanzetta, Italy; José Cunha-Vaz, Portugal</u>	
11:00-11:30	Debate 1: Corticosteroids are Warranted in the Management of Chronic DME in Phakic Eye	
11:00-11:10	Yes: <u>Baruch Kupperman, USA</u>	
11:10-11:20	No: <u>Susan Bressler, USA</u>	
11:20-11:30	Discussion	
11:30-12:00	Debate 2: Anti-VEGF Should Be Tried Prior to Vitrectomy for Vitreous Hemorrhage from PDR	
11:30-11:40	Yes: <u>Luis Arias, Spain</u>	
11:40-11:50	No: <u>Jun Kong, China</u>	
11:50-12:00	Discussion	
12:00-12:30	Debate 3: Ang2-inhibition Offers the Potential for Greater Visual Acuity and Duration Benefits for DME compared with Current Anti-VEGF Agents	
12:00-12:10	Yes: <u>Sandrine Zweifel, Switzerland</u>	
12:10-12:20	No: <u>Patricia Udaondo, Spain</u>	
12:20-12:30	Discussion	
12:30-13:00	<i>Visit Companies Information Corner and ePosters</i>	
13:00-14:00	Industry-Sponsored Symposium	
14:00-14:15	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

MEDICAL RETINA 3 | Potentially Longer Acting Strategies

Saturday August 21, 2021		Hall A
14:15-15:45	MEDICAL RETINA 3 Potentially Longer Acting Strategies	
Chairs:	<u>Gemmy Cheung</u>, Singapore; <u>Stela Vujosevic</u>, Italy	
14:15-14:45	Debate 1: Port Delivery Systems Should be Used in DME When Approved	
14:15-14:25	Yes: <u>Dante Pieramici</u>, USA	
14:25-14:35	No: <u>Michaella Goldstein</u>, Israel	
14:35-14:45	Discussion	
14:45-15:15	Debate 2: PCV Treatment Typically Should Combine Anti-VEGF with PDT	
14:45-14:55	Yes: <u>Adrian Koh</u>, Singapore	
14:55-15:05	No: <u>Gemmy Cheung</u>, Singapore	
15:05-15:15	Discussion	
15:15-15:45	Debate 3: Potentially Longer Acting Strategies Should be Considered for Myopic Neovascularization over Currently Available Agents	
15:15-15:25	Yes: <u>Michaella Goldstein</u>, Israel	
15:25-15:35	No: <u>Kyoko Ohno-Matsui</u>, Japan	
15:35-15:45	Discussion	
15:45-16:00	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

MEDICAL RETINA 4 | AMD and Hereditary Retinal Degeneration Topics

Saturday August 21, 2021		Hall A
16:00-17:30	MEDICAL RETINA 4 AMD and Hereditary Retinal Degeneration Topics	
Chairs:	<u>Hendrik Scholl</u> , Switzerland; <u>Jean-Francois Korobelnik</u> , France; <u>Rufino Silva</u> , Portugal	
16:00-16:30	Debate 1: Gene Therapy is a Promising Strategy in the Management of Pattern Dystrophies	
16:00-16:10	Yes: <u>Isabelle Audo</u> , France	
16:10-16:20	No: <u>Hendrik Scholl</u> , Switzerland	
16:20-16:30	Discussion	
16:30-17:00	Debate 2: Home Monitoring to Detect Onset of Choroidal Neovascularization will Improve Visual Acuity Outcomes	
16:30-16:40	Yes: <u>Onnisa Nanegrungsunk</u> , Thailand	
16:40-16:50	No: <u>Paul Mitchell</u> , Australia	
16:50-17:00	Discussion	
17:00-17:30	Debate 3: Genetic Testing is Warranted in Pattern Dystrophy Phenotypes	
17:00-17:10	Yes: <u>Hendrik Scholl</u> , Switzerland	
17:10-17:20	No: <u>Itay Chowers</u> , Israel	
17:20-17:30	Discussion	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

HALL B

SURGICAL RETINA | NOVEL PROCEDURES AND SURGICAL SYSTEMS

Friday, August 20, 2021

Hall B

13:00-14:30	SURGICAL RETINA Novel Procedures and Surgical Systems
Chairs:	<u>William Mieler, USA</u>; <u>Stanislao Rizzo, Italy</u>, <u>Joseph Moisseiev, Israel</u>; <u>Stratos Gotzaridis, Greece</u>
13:00-13:30	Debate 1: Voretigene Neparvovec-RZYL is a Viable Approach to Hereditary Retinal Degenerations
13:00-13:10	Yes: <u>William Mieler, USA</u>
13:10-13:20	No: <u>Francesco Boscia, Italy</u>
13:20-13:30	Discussion
13:30-14:00	Debate 2: 3D Monitors are Preferable to Surgical Microscope Systems
13:30-13:40	Yes: <u>Stanislao Rizzo, Italy</u>
13:40-13:50	No: <u>Elad Moisseiev, Israel</u>
13:50-14:00	Discussion
14:00-14:30	Debate 3: Vitrectomy is Warranted for Worsening Myopic Macular Schisis in the Absence of Vitreomacular Traction
14:00-14:10	Yes: <u>Taiji Sakamoto, Japan</u>
14:10-14:20	No: <u>Joseph Moisseiev, Israel</u>
14:20-14:30	Discussion
14:30-15:00	<i>Visit Companies Information Corner and ePosters</i>

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

NEURO-OPHTHALMOLOGY 1 | The Afferent Pathway

Saturday August 21, 2021		Hall B
11:00-12:30	NEURO-OPHTHALMOLOGY 1 The Afferent Pathway	
Chairs:	<u>Andrew Lee, USA</u>; <u>Susan Mollan, UK</u>	
11:00-11:30	Debate 1: Patients with Acute Optic Neuritis Typically Should Have an Assay for Anti-Aquaporin-4 Antibodies, Anti-MOG Antibodies, or Both	
11:00-11:10	Yes: <u>Prem S. Subramanian, USA</u>	
11:10-11:20	No: <u>Andrew Lee, USA</u>	
11:20-11:30	Discussion	
11:30-12:00	Debate 2: Patients with "Typical" Acute Optic Neuritis Usually Should be Treated with IV Methylprednisolone	
11:30-11:40	Yes: <u>Andrew Lee, USA</u>	
11:40-11:50	No: <u>Susan Mollan, UK</u>	
11:50-12:00	Discussion	
12:00-12:30	Case Presentations	
	Moderator: <u>Andrew Lee, USA</u>	
	Panelists: <i>All Speakers</i>	
	<ol style="list-style-type: none"> 1. A Young Man with Loss of Vision After Blunt Head Trauma 2. A Young Man With Painless Bilateral Sequential Visual Loss 3. A Child With Decreased Vision 4. An Older Woman With Sudden Painless Visual Loss 5. An Older Man With Episodes Of Transient Monocular Visual Loss 	
12:30-13:00	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

UVEITIS

Saturday August 21, 2021		Hall B
14:15-15:45	UVEITIS	
Chairs:	<u>Bahram Bodaghi, France; Zohar Habot-Wilner, Israel</u>	
14:15-14:45	Debate 1: Long Acting Intravitreal Corticosteroids for the Treatment of Noninfectious Posterior Segment Uveitis is Better than Systemic Treatment	
14:15-14:25	Yes: <u>Bahram Bodaghi, France</u>	
14:25-14:35	No: <u>Douglas Jabs, USA</u>	
14:35-14:45	Discussion	
14:45-15:15	Debate 2: Topical Prostaglandins May be Used in Uveitic Hypertension/Glaucoma	
14:45-14:55	Yes: <u>Zohar Habot-Wilner, Israel</u>	
14:55-15:05	No: <u>Sofia Androudi, Greece</u>	
15:05-15:15	Discussion	
15:15-15:45	Debate 3: OCT-Angiography is a Must-Have Tool for the Management of White Dot Syndromes	
15:15-15:25	Yes: <u>Bahram Bodaghi, France</u>	
15:25-15:35	No: <u>Zohar Habot-Wilner, Israel</u>	
15:35-15:45	Discussion	
15:45-16:00	<i>Visit Companies Information Corner and ePosters</i>	

PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)

NEURO-OPHTHALMOLOGY 2 | The Efferent Pathway and Systemic Disorders

Saturday August 21, 2021		Hall B
16:00-17:30	NEURO-OPHTHALMOLOGY 2 The Efferent Pathway and Systemic Disorders	
Chairs:	TBC; <u>Prem S. Subramanian, USA</u>	
16:00-16:30	Debate 1: A Patient With an Acute 6th Nerve Palsy Who is Over Age 50 and Who has Vascular Risk Factors Typically Requires Neuroimaging	
16:00-16:10	Yes: <u>Andrew Lee, USA</u>	
16:10-16:20	No: <u>Susan Mollan, UK</u>	
16:20-16:30	Discussion	
16:30-17:00	Debate 2: A Temporal Artery Biopsy is Necessary in Almost Every Patient with Suspected Giant Cell Arteritis	
16:30-16:40	Yes: <u>Andrew Lee, USA</u>	
16:40-16:50	No: <u>Prem S. Subramanian, USA</u>	
16:50-17:00	Discussion	
17:00-17:30	Case Presentations	
	Moderator: <u>Andrew Lee, USA</u>	
	Panelists: <i>All Speakers</i>	
	<ol style="list-style-type: none"> 1. A Woman with Ptosis and Diplopia 2. A Man with Ptosis and Diplopia 3. A Child with Strabismus 4. A Child with Funny Eye Movements 5. A Elderly Man with Diplopia 	